Courtagen Life Sciences Appoints Helio Pedro, MD to the Company's Clinical And Strategic Advisory Board.

WOBURN, Mass.--(BUSINESS WIRE)--

Courtagen Life Sciences, Inc., an innovative molecular information company, announced today the appointment of Dr. Helio Pedro to the company's Clinical and Strategic Advisory Board.

"Dr. Pedro brings strong clinical genetics and biochemical experience to our firm. Dr. Pedro will add a valuable perspective to our clinical team," states Brian McKernan, Chief Executive Officer of Courtagen. "We look forward to benefiting from Dr. Pedro's insights as we continue to build a world class molecular information company to help the lives of our patients."

Dr. Helio Pedro received his Bachelor of Science degree in Biochemistry from the State University of New York at Stony Brook. He then proceeded to obtain his medical degree from St. George's University School of Medicine. He completed a joint residency program at UMDNJ in Internal Medicine and Pediatrics, following which he worked in private practice for 2 years. Afterwards, he returned to UMDNJ to pursue a fellowship in both Clinical Genetics and Clinical Biochemical Genetics. Upon completing his fellowship, he remained at UMDNJ as an Assistant Professor of Pediatrics in the Department of Genetics, and worked jointly with the Division of Genetics at Hackensack University Medical Center. He left UMDNJ in 2009 after being appointed Chief of the Division of Genetics at Hackensack University Medical Center where he is still practicing. Dr. Pedro is board certified by the American Academy of Pediatrics and by the American Board of Medical Genetics in both Clinical Genetics and Clinical Biochemical Genetics. His areas of interest include clinical genetics, adult genetics, and biochemical genetics.

About Courtagen Life Sciences, Inc.

Courtagen is a privately held life sciences and molecular information company that converts genomic data into actionable clinical information for the diagnosis of critical pediatric neurological and metabolic disorders. Specifically, Courtagen focuses on mitochondrial disorders, epilepsy, and intellectual disability, including autism spectrum disorders. Courtagen's state-of-the-art Next-Generation Sequencing clinical laboratory integrates genotype, phenotype, and disease mechanism data using cloud-based computing and custom analytical methods to provide the most comprehensive results for clinicians, patients, and their families to better understand and treat their disease. More information can be found at www.courtagen.com.